vs
Forestar Group Inc.（FOR）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Forestar Group Inc.的季度营收约是VERACYTE, INC.的1.9倍（$273.0M vs $140.6M），VERACYTE, INC.净利率更高（29.3% vs 5.6%，领先23.6%），VERACYTE, INC.同比增速更快（18.5% vs 9.0%），VERACYTE, INC.自由现金流更多（$48.8M vs $-157.1M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -9.6%）
福雷斯特集团是一家住宅地块开发企业，总部位于得克萨斯州阿灵顿，业务覆盖美国21个州的51个市场。截至2020年12月31日的12个月内，该公司交付了11518块住宅地块，目前在纽约证券交易所上市，自2002年起就是美国规模最大的住宅建筑商D.R. Horton的控股子公司。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
FOR vs VCYT — 直观对比
营收规模更大
FOR
是对方的1.9倍
$140.6M
营收增速更快
VCYT
高出9.5%
9.0%
净利率更高
VCYT
高出23.6%
5.6%
自由现金流更多
VCYT
多$205.9M
$-157.1M
两年增速更快
VCYT
近两年复合增速
-9.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $273.0M | $140.6M |
| 净利润 | $15.4M | $41.1M |
| 毛利率 | 20.1% | 72.5% |
| 营业利润率 | 7.6% | 26.4% |
| 净利率 | 5.6% | 29.3% |
| 营收同比 | 9.0% | 18.5% |
| 净利润同比 | -6.7% | 704.8% |
| 每股收益（稀释后） | $0.30 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORVCYT
| Q4 25 | $273.0M | $140.6M | ||
| Q3 25 | $670.5M | $131.9M | ||
| Q2 25 | $390.5M | $130.2M | ||
| Q1 25 | $351.0M | $114.5M | ||
| Q4 24 | $250.4M | $118.6M | ||
| Q3 24 | $551.3M | $115.9M | ||
| Q2 24 | $318.4M | $114.4M | ||
| Q1 24 | $333.8M | $96.8M |
净利润FORVCYT
| Q4 25 | $15.4M | $41.1M | ||
| Q3 25 | $86.9M | $19.1M | ||
| Q2 25 | $32.9M | $-980.0K | ||
| Q1 25 | $31.6M | $7.0M | ||
| Q4 24 | $16.5M | $5.1M | ||
| Q3 24 | $81.5M | $15.2M | ||
| Q2 24 | $38.7M | $5.7M | ||
| Q1 24 | $45.0M | $-1.9M |
毛利率FORVCYT
| Q4 25 | 20.1% | 72.5% | ||
| Q3 25 | 22.3% | 69.2% | ||
| Q2 25 | 20.4% | 69.0% | ||
| Q1 25 | 22.6% | 69.5% | ||
| Q4 24 | 22.0% | 66.4% | ||
| Q3 24 | 23.9% | 68.2% | ||
| Q2 24 | 22.5% | 68.1% | ||
| Q1 24 | 24.9% | 64.5% |
营业利润率FORVCYT
| Q4 25 | 7.6% | 26.4% | ||
| Q3 25 | 16.9% | 17.4% | ||
| Q2 25 | 11.2% | -4.0% | ||
| Q1 25 | 11.6% | 2.5% | ||
| Q4 24 | 8.7% | 3.5% | ||
| Q3 24 | 19.7% | 10.4% | ||
| Q2 24 | 16.2% | 4.0% | ||
| Q1 24 | 17.6% | -4.8% |
净利率FORVCYT
| Q4 25 | 5.6% | 29.3% | ||
| Q3 25 | 13.0% | 14.5% | ||
| Q2 25 | 8.4% | -0.8% | ||
| Q1 25 | 9.0% | 6.2% | ||
| Q4 24 | 6.6% | 4.3% | ||
| Q3 24 | 14.8% | 13.1% | ||
| Q2 24 | 12.2% | 5.0% | ||
| Q1 24 | 13.5% | -1.9% |
每股收益（稀释后）FORVCYT
| Q4 25 | $0.30 | $0.50 | ||
| Q3 25 | $1.70 | $0.24 | ||
| Q2 25 | $0.65 | $-0.01 | ||
| Q1 25 | $0.62 | $0.09 | ||
| Q4 24 | $0.32 | $0.07 | ||
| Q3 24 | $1.59 | $0.19 | ||
| Q2 24 | $0.76 | $0.07 | ||
| Q1 24 | $0.89 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.7M | $362.6M |
| 总债务越低越好 | $793.2M | — |
| 股东权益账面价值 | $1.8B | $1.3B |
| 总资产 | $3.2B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资FORVCYT
| Q4 25 | $211.7M | $362.6M | ||
| Q3 25 | $379.2M | $315.6M | ||
| Q2 25 | $189.2M | $219.5M | ||
| Q1 25 | $174.3M | $186.1M | ||
| Q4 24 | $132.0M | $239.1M | ||
| Q3 24 | $481.2M | $274.1M | ||
| Q2 24 | $359.2M | $235.9M | ||
| Q1 24 | $416.2M | $209.2M |
总债务FORVCYT
| Q4 25 | $793.2M | — | ||
| Q3 25 | $802.7M | — | ||
| Q2 25 | $872.8M | — | ||
| Q1 25 | $872.5M | — | ||
| Q4 24 | $806.8M | — | ||
| Q3 24 | $706.4M | — | ||
| Q2 24 | $706.1M | — | ||
| Q1 24 | $705.7M | — |
股东权益FORVCYT
| Q4 25 | $1.8B | $1.3B | ||
| Q3 25 | $1.8B | $1.3B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.6B | $1.2B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.5B | $1.1B |
总资产FORVCYT
| Q4 25 | $3.2B | $1.4B | ||
| Q3 25 | $3.1B | $1.4B | ||
| Q2 25 | $3.1B | $1.3B | ||
| Q1 25 | $3.0B | $1.3B | ||
| Q4 24 | $3.0B | $1.3B | ||
| Q3 24 | $2.8B | $1.3B | ||
| Q2 24 | $2.7B | $1.2B | ||
| Q1 24 | $2.6B | $1.2B |
负债/权益比FORVCYT
| Q4 25 | 0.44× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-157.0M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-157.1M | $48.8M |
| 自由现金流率自由现金流/营收 | -57.5% | 34.7% |
| 资本支出强度资本支出/营收 | 0.0% | 2.7% |
| 现金转化率经营现金流/净利润 | -10.19× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $93.0M | $126.6M |
8季度趋势，按日历期对齐
经营现金流FORVCYT
| Q4 25 | $-157.0M | $52.6M | ||
| Q3 25 | $256.3M | $44.8M | ||
| Q2 25 | $15.8M | $33.6M | ||
| Q1 25 | $-19.8M | $5.4M | ||
| Q4 24 | $-450.0M | $24.5M | ||
| Q3 24 | $119.2M | $30.0M | ||
| Q2 24 | $-61.7M | $29.6M | ||
| Q1 24 | $-59.2M | $-9.0M |
自由现金流FORVCYT
| Q4 25 | $-157.1M | $48.8M | ||
| Q3 25 | $255.6M | $42.0M | ||
| Q2 25 | $15.0M | $32.3M | ||
| Q1 25 | $-20.5M | $3.5M | ||
| Q4 24 | — | $20.4M | ||
| Q3 24 | $118.4M | $27.7M | ||
| Q2 24 | $-62.3M | $26.8M | ||
| Q1 24 | $-59.8M | $-11.1M |
自由现金流率FORVCYT
| Q4 25 | -57.5% | 34.7% | ||
| Q3 25 | 38.1% | 31.8% | ||
| Q2 25 | 3.8% | 24.8% | ||
| Q1 25 | -5.8% | 3.1% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | 21.5% | 23.9% | ||
| Q2 24 | -19.6% | 23.4% | ||
| Q1 24 | -17.9% | -11.5% |
资本支出强度FORVCYT
| Q4 25 | 0.0% | 2.7% | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.2% | 1.6% | ||
| Q4 24 | 0.0% | 3.5% | ||
| Q3 24 | 0.1% | 1.9% | ||
| Q2 24 | 0.2% | 2.4% | ||
| Q1 24 | 0.2% | 2.2% |
现金转化率FORVCYT
| Q4 25 | -10.19× | 1.28× | ||
| Q3 25 | 2.95× | 2.34× | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -0.63× | 0.76× | ||
| Q4 24 | -27.27× | 4.80× | ||
| Q3 24 | 1.46× | 1.98× | ||
| Q2 24 | -1.59× | 5.16× | ||
| Q1 24 | -1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
